State University of New York Upstate Medical University

Now Available in Pennsylvania: New Virtual Clinic Focuses on Diagnosing Autism Sooner

Retrieved on: 
Monday, August 1, 2022
Knowledge, Diagnosis, View, Physician, State University of New York Upstate Medical University, Parent, Multimedia, Autism, Patient, Pediatrics, Residential care, Hospital

HARRISBURG, Pa., Aug. 1, 2022 /PRNewswire/ -- Early diagnosis is crucial for children with autism, yet parents can face very long wait times to receive answers. A new virtual clinic called As You Are aims to solve this problem by increasing access to a team of pediatricians who provide evaluations for autism to children 16 months to 10 years old using exclusively telehealth appointments. Families who complete the As You Are assessment process can receive a diagnosis in less than one month.

Key Points: 
  • A new virtual clinic called As You Are aims to solve this problem by increasing access to a team of pediatricians who provide evaluations for autism to children 16 months to 10 years old using exclusively telehealth appointments.
  • Families who complete the As You Are assessment process can receive a diagnosis in less than one month.
  • "Starting interventions during the early developmental period is critical for children, yet today, the wait times for an evaluation for autism can be between 12-30 months.
  • "There is a significant need across our country for autism diagnoses to be made earlier to help our next generations thrive."

Now Available in Ohio: New Virtual Clinic Focuses on Diagnosing Autism Sooner

Retrieved on: 
Monday, August 1, 2022
Knowledge, Diagnosis, View, Physician, State University of New York Upstate Medical University, Parent, Multimedia, Autism, Patient, Pediatrics, Residential care, Hospital

COLUMBUS, Ohio, Aug. 1, 2022 /PRNewswire/ -- Early diagnosis is crucial for children with autism, yet parents can face very long wait times to receive answers. A new virtual clinic called As You Are aims to solve this problem by increasing access to a team of pediatricians who provide evaluations for autism to children 16 months to 10 years old using exclusively telehealth appointments. Families who complete the As You Are assessment process can receive a diagnosis in less than one month.

Key Points: 
  • A new virtual clinic called As You Are aims to solve this problem by increasing access to a team of pediatricians who provide evaluations for autism to children 16 months to 10 years old using exclusively telehealth appointments.
  • Families who complete the As You Are assessment process can receive a diagnosis in less than one month.
  • "Starting interventions during the early developmental period is critical for children, yet today, the wait times for an evaluation for autism can be between 12-30 months.
  • "There is a significant need across our country for autism diagnoses to be made earlier to help our next generations thrive."

Now Available in New Jersey: New Virtual Clinic Focuses on Diagnosing Autism Sooner

Retrieved on: 
Monday, August 1, 2022
Knowledge, Diagnosis, View, Physician, State University of New York Upstate Medical University, Parent, Multimedia, Autism, Patient, Pediatrics, Residential care, Hospital

TRENTON, N.J., Aug. 1, 2022 /PRNewswire/ -- Early diagnosis is crucial for children with autism, yet parents can face very long wait times to receive answers. A new virtual clinic called As You Are aims to solve this problem by increasing access to a team of pediatricians who provide evaluations for autism to children 16 months to 10 years old using exclusively telehealth appointments. Families who complete the As You Are assessment process can receive a diagnosis in less than one month.

Key Points: 
  • A new virtual clinic called As You Are aims to solve this problem by increasing access to a team of pediatricians who provide evaluations for autism to children 16 months to 10 years old using exclusively telehealth appointments.
  • Families who complete the As You Are assessment process can receive a diagnosis in less than one month.
  • "Starting interventions during the early developmental period is critical for children, yet today, the wait times for an evaluation for autism can be between 12-30 months.
  • "There is a significant need across our country for autism diagnoses to be made earlier to help our next generations thrive."

Now Available in Kentucky: New Virtual Clinic Focuses on Diagnosing Autism Sooner

Retrieved on: 
Monday, August 1, 2022
Knowledge, Diagnosis, View, Physician, State University of New York Upstate Medical University, Parent, Multimedia, Autism, Patient, Pediatrics, Residential care, Hospital

FRANKFORT, Ky., Aug. 1, 2022 /PRNewswire/ -- Early diagnosis is crucial for children with autism, yet parents can face very long wait times to receive answers. A new virtual clinic called As You Are aims to solve this problem by increasing access to a team of pediatricians who provide evaluations for autism to children 16 months to 10 years old using exclusively telehealth appointments. Families who complete the As You Are assessment process can receive a diagnosis in less than one month.

Key Points: 
  • A new virtual clinic called As You Are aims to solve this problem by increasing access to a team of pediatricians who provide evaluations for autism to children 16 months to 10 years old using exclusively telehealth appointments.
  • Families who complete the As You Are assessment process can receive a diagnosis in less than one month.
  • "Starting interventions during the early developmental period is critical for children, yet today, the wait times for an evaluation for autism can be between 12-30 months.
  • "There is a significant need across our country for autism diagnoses to be made earlier to help our next generations thrive."

Now Available in Alabama: New Virtual Clinic Focuses on Diagnosing Autism Sooner

Retrieved on: 
Monday, August 1, 2022
Knowledge, Diagnosis, View, Physician, State University of New York Upstate Medical University, Parent, Multimedia, Autism, Patient, Pediatrics, Residential care, Hospital

MONTGOMERY, Ala., Aug. 1, 2022 /PRNewswire/ -- Early diagnosis is crucial for children with autism, yet parents can face very long wait times to receive answers. A new virtual clinic called As You Are aims to solve this problem by increasing access to a team of pediatricians who provide evaluations for autism to children 16 months to 10 years old using exclusively telehealth appointments. Families who complete the As You Are assessment process can receive a diagnosis in less than one month.

Key Points: 
  • A new virtual clinic called As You Are aims to solve this problem by increasing access to a team of pediatricians who provide evaluations for autism to children 16 months to 10 years old using exclusively telehealth appointments.
  • Families who complete the As You Are assessment process can receive a diagnosis in less than one month.
  • "Starting interventions during the early developmental period is critical for children, yet today, the wait times for an evaluation for autism can be between 12-30 months.
  • "There is a significant need across our country for autism diagnoses to be made earlier to help our next generations thrive."

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

Retrieved on: 
Monday, July 25, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Allergy, Antibody, AK002, AAOS, Stanford University Medical Center, Stanford University, Inflammation, Time, American Academy, Skin, GLOBE, University, American Academy of Orthopaedic Surgeons, State University of New York Upstate Medical University, History, Atopic dermatitis, Food, SAN, SEC, Lirentelimab, B cell, Immunology, Private Securities Litigation Reform Act, Securities Act of 1933, EOE, Securities Exchange Act of 1934, EOD, Safety, Board, Cell, Intuitive Surgical, Dartmouth College, Eosinophilic esophagitis, William H. Harris (orthopaedic surgeon), Company, Gastrointestinal tract, Patient, Orthopedic surgery, Specialty Society Relative Value Scale Update Committee, Professor, Therapy, Annual report, Rochester, EG, Drug Quality and Security Act, Eosinophil, Pharmaceutical industry

We are very pleased to have such an accomplished physician as Dr. Ladd join our board.

Key Points: 
  • We are very pleased to have such an accomplished physician as Dr. Ladd join our board.
  • Dr. Ladd is also a member of the board of directors for Intuitive Surgical, Inc. and the Perry Initiative.
  • Previously, she served as the chair of the American Academy of Orthopaedic Surgeons (AAOS) Board of Specialties Society and is a past member of the AAOS board of directors.
  • These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos forward-looking statements.

Stephen J. Thomas, M.D., Joins Rheonix Board and Executive Team

Retrieved on: 
Thursday, July 21, 2022
Health, FDA, Infectious Diseases, Clinical Trials, Research, Science, Biotechnology, Virus, Male, Beer, STI, State University of New York Upstate Medical University, Internal medicine, Urine, Inc., CEO, Immunology, Government, Albany Medical College, Walter Reed Army Institute of Research, Institute, Infection, Board, Global Health, Secondary research, Walter Reed Army Medical Center, Brown University, Middle East respiratory syndrome–related coronavirus, FDA, Army of the United States, Patient, COVID, Department, Microbiology, Upstate, Vaccine, Pharmaceutical industry, Research, Listeria, Zika fever

Rheonix Inc ., an innovative leader in highly multiplexed pathogen detection, announced the appointment of Stephen J. Thomas, M.D., as Chief Medical Officer and member of the Rheonix Board of Directors.

Key Points: 
  • Rheonix Inc ., an innovative leader in highly multiplexed pathogen detection, announced the appointment of Stephen J. Thomas, M.D., as Chief Medical Officer and member of the Rheonix Board of Directors.
  • I am delighted to welcome Dr. Thomas to the Rheonix Board and as our Chief Medical Officer, said Greg Galvin, President, CEO and Chairman of the Board of Directors of Rheonix.
  • His extensive experience leading U.S. government responses to emerging and epidemic infectious diseases will be invaluable to Rheonix as we continue to build our clinical diagnostic portfolio.
  • The Rheonix Encompass workstations enable highly multiplexed sample-to-answer molecular testing for use in clinical, research and applied testing laboratories.

ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy

Retrieved on: 
Wednesday, June 29, 2022
FDA, Assistant, Patient, Sarcocystis neurona, Biopsy, Gamma-Aminobutyric acid, Research, Brain, GLOBE, COVID-19, Growth, CNS, GABA, Company, U.S. Securities and Exchange Commission, Lists of diseases, Seizure, Therapy, State University of New York Upstate Medical University, Particular, Doctor of Philosophy, Neurosurgery, Nasdaq, Quality of life, Temporal lobe epilepsy, Solution, MD, Security (finance), Epilepsy, Pharmaceutical industry

An estimated three million Americans have epilepsy, and 25 to 35 percent live with ongoing seizures despite dozens of approved drugs on the market.

Key Points: 
  • An estimated three million Americans have epilepsy, and 25 to 35 percent live with ongoing seizures despite dozens of approved drugs on the market.
  • The first stage of the trial is an open-label dose-escalation study in up to 10 patients with MTLE.
  • Our team is proud to partner with Neurona to support their Phase 1/2 clinical trial of what could potentially be a breakthrough regenerative cell therapy for MTLE.
  • ClearPoint Neuro is partnered with approximately 45 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.

Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

Retrieved on: 
Wednesday, June 29, 2022
Cell, Neurosurgery, CIRM, Gamma-Aminobutyric acid, Patient, Brain, Regenerative medicine, GLOBE, Temporal lobe, GABA, Seizure, Lists of diseases, SAN, Neurology, California Institute for Regenerative Medicine, State University of New York Upstate Medical University, Clinical trial, GABAergic, Hippocampus, Temporal lobe epilepsy, Safety, Program, Work, Therapy, Epilepsy, Interneuron, Pharmaceutical industry, Sarcocystis neurona

SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, today announced the first patient dosed in a Phase 1/2 clinical trial of its lead program, NRTX-1001, in a first-in-human epilepsy study. An estimated three million Americans have epilepsy, and 25 to 35 percent live with ongoing seizures despite dozens of approved drugs on the market, which means that there is a huge unmet medical need in this community. NRTX-1001 is a regenerative neural cell therapy delivered as a single dose and designed to provide long-term secretion of gamma-aminobutyric acid (GABA), a key inhibitory neurotransmitter, to repair hyper-excitable neural networks associated with mesial temporal lobe epilepsy (MTLE), the most common form of focal epilepsy in adults.

Key Points: 
  • We are very excited to take this next step, bringing a first-in-class, novel regenerative treatment to people living with chronic focal seizures.
  • We are delighted to work with the Neurona team to evaluate the potential of this exciting new therapeutic approach.
  • Neuronas multicenter, Phase 1/2 clinical trial is designed to evaluate the safety and efficacy of a single administration of NRTX-1001 for drug-resistant MTLE.
  • The first part of the clinical trial is supported by a recently announced $8.0 million grant from the California Institute for Regenerative Medicine (CIRM; CLIN2-13355).

Noridian expands commercial market expertise with new position and hire

Retrieved on: 
Tuesday, June 14, 2022
Program, LLC, Knowledge, Risk-adjusted return on capital, AHIP, Solution, State university system, University, Stony Brook, GLOBE, Accuro Healthcare Solutions, Psychology, State University of New York Upstate Medical University, History of the University of Maryland, College Park, Management, Medicine, Noridian Mutual Insurance Company

FARGO, N.D., June 14, 2022 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, has expanded its commercial market reach with the addition of a new position.

Key Points: 
  • FARGO, N.D., June 14, 2022 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, has expanded its commercial market reach with the addition of a new position.
  • Jennie ML Ossentjuk joins Noridian as the market lead of commercial health plans and will serve as a central point of contact for health plan administration networks.
  • For more than 60 years, Noridian has been the trusted source for federal and state health care administration solutions.
  • We are eager to strengthen our commercial market presence with Jennies long-established leadership and industry expertise, shares Woody Barela, senior vice president and chief growth officer at Noridian.